por John R. Fischer
, Senior Reporter | April 15, 2021
Medline Industries, a developer and supplier of PPE and other medical products, is looking into a possible sale of its company that could be worth as much as $30 billion.
While there is not yet any certainty of a sale, the company is said to have hired Goldman Sachs Groups Inc. to explore the option of one, as well as an IPO or minority investment, according to The Wall Street Journal
If such a deal were in the works, it would likely attract private-equity bidders due to their having more resources and capital to buy-out and integrate Medline Industries into their operations. Among those said to be considering bids are Blackstone Group Inc., KKR & Co. and Carlyle Group Inc., reports The Wall Street Journal.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Medline Industries previously acquired the NAMIC fluid management portfolio of AngioDynamics
in 2019 for $167.5 million. This included AngioDynamics’ offerings of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories.
It also entered into a $120 million partnership
in June 2020 with the University of Texas System Supply Chain Alliance to distribute PPE and other supplies to UT System's three acute care institutions: UT Southwestern Medical Center in Dallas, UT MD Anderson Cancer Center in Houston and UT Medical Branch in Galveston.
That same month, Medline announced a $12 million prime vendor partnership
with Yuma Regional Medical Center to identify new strategies for enhancing operational and clinical efficiencies across the acute care hospital and multiple ambulatory facilities.
The company manufactures and distributes surgical gowns, examination gloves and various types of diagnostic equipment.
Medline Industries did not respond for comment.